Background {#Sec1}
==========

Coronary heart disease is the leading cause of death and disability worldwide and is responsible for about 7.2 million deaths every year. Cardiac surgery is one of the most common cardiac procedures, performed annually in about 1.5 million patients worldwide. In spite of advances in surgical techniques, the incidence of complications after cardiac surgery using cardiopulmonary bypass is still high. The most common complications following cardiac surgery are atrial fibrillation (AF), delirium, myocardial infarction (MI), acute renal failure and stroke, all of which increase mortality and lead to a prolonged stay on intensive care unit (ICU) of patients. The restoration of regional blood flow after a period of ischemia during cardiac surgery frequently causes further cellular organ injury and thereby potentially limiting the recovery of function. Reperfusion is often associated with microvascular dysfunction. Activated endothelial cells produce excessive reactive oxygen species (ROS), but less nitric oxide, leading to release of inflammatory mediators, mitochondrial dysfunction, oxidative stress and finally cell death \[[@CR1]\].

Yet, the inflammatory mediators released as a consequence of reperfusion also appear to activate endothelial cells in remote organs not initially exposed to the ischemic stress, i.e. the kidney and the central nervous system. This distant response to ischemia/ reperfusion (I/R) can result in leukocyte-dependent microvascular injury that is characteristic of the "systemic inflammatory response syndrome", potentially leading to delirium, stroke and acute kidney dysfunction \[[@CR2]\].

Hypercholesterolemia, diabetes and hypertension, the occurrence and extent of complications after cardiac surgery could have a genetic basis. A genetic bias is strongly suggested by observations that the wide variability concerning incidence and severity of complications after cardiac surgery could not be explained by clinical or interventional risks. As postoperative organ dysfunction is common after cardiac surgery, several previous studies have performed preoperative genomic characterization of patients to identify genotypes, which render the patients vulnerable for the development of a specific organ dysfunction. Kertai et al. identified genetic variants in patients exhibiting AF and MI after cardiac surgery \[[@CR3], [@CR4]\]. Another recent study reported genetic variants concerning acute kidney injury after cardiac surgery \[[@CR5]\]. All of these studies investigated one or two complications after cardiac surgery but none examined the complications in all, nor investigated a composite of all main complications. Therefore, we conducted a comprehensive genome-wide association study (GWAS) to identify common genetic variants associated with the main complications after cardiac surgery as new-onset postoperative AF, MI, delirium, stroke and acute renal failure.

Methods {#Sec2}
=======

We performed a GWAS using in total 1170 DNA samples from the RIPHeart (Remote Ischemic Preconditioning for Heart Surgery) study cohort \[[@CR6], [@CR7]\] (871 males, 299 females) in the dataset testing 547,644 variants to identify candidate genes that predetermine main complications after cardiac surgery. Various samples were excluded for the different subanalyses. See below (statistics) for more information.

The initial objective of our prospective, double-blind, multicentre, randomized controlled RIPHeart study was to investigate whether upper limb remote ischemic preconditioning compared to sham intervention reduced the incidence of the primary endpoint including death, MI, stroke, and acute renal failure until hospital discharge in adults scheduled for elective cardiac surgery requiring cardiopulmonary bypass (for further information please read the english synopsis and study protocol of the RIPHeart study in Additional file [1](#MOESM1){ref-type="media"}: Figure S3 and Additional file [2](#MOESM2){ref-type="media"}: Figure S4 in the supplementary). As the initial intervention study did not show any group differences, this predefined secondary analysis of genome-wide association now includes all patients irrespective of the initial group assignment.

Patient populations {#Sec3}
-------------------

The cohort comprised 1204 patients who underwent an elective cardiac surgery requiring cardiopulmonary bypass (e.g. coronary artery bypass graft, valve surgery, ascending aorta replacement) between January 2011 and May 2014 and were analysed. 1170 (871 males, 299 females) patients met eligibility criteria after applying quality control and excluding patients with missing genotypes or phenotypic information.

Outcome measures {#Sec4}
----------------

In this GWAS-study, the primary endpoint comprises a composite complication rate covering AF, delirium, MI, acute renal failure, and/or any new stroke. Non-fatal myocardial infarction was defined bybiomarker values more than five times the 99th percentile of the normal reference range combined with new pathological Q-wavesor new left bundle branch block (LBBB) within the first 72 hstandard clinical criteria for myocardial infarction from 72 h onnew ischemic finding by echocardiography/angiographyor myocardial infarction diagnosed at autopsy.

Some patients present with ST elevation or new LBBB, and suffer sudden cardiac death before cardiac biomarkers become abnormal or pathological signs of myocardial necrosis become evident at autopsy. These patients should be classified as having had a fatal myocardial infarction \[[@CR8]\].

A blinded clinical endpoint committee assessed all available electrocardiograms for reference reading. Stroke was defined by any new, temporary or permanent, focal or global neurological deficit, or evidence of stroke on autopsy, and was evaluated according to the National Institutes of Health Stroke Scale (≥ 4 points) \[[@CR9]\]. Acute renal failure was defined by any serum creatinine greater than or equal to two-fold increase from baseline, urine output ≤0.5 mL/kg/h for 12 h \[[@CR10]\], use of renal replacement therapy, or evidence of renal failure on autopsy. New onset of AF was recorded by electrocardiograms. Delirium was assessed with the CAM-ICU score \[[@CR11]\].

While delirium and AF were recorded within 4 days after surgery, MI, stroke and acute renal failure were analyzed until hospital discharge with a maximum of 14 days after surgery. Additionally several other clinical variables were recorded. For details see Table [1](#Tab1){ref-type="table"}.Table 1Baseline Patient CharacteristicsVariable*N* = 1170Age -- yr65.7 ± 10.3Male sex --- no./total no. (%)865/1163 (74.4%)Preexisting conditions --- no./total no. (%) Ischemic heart disease859/1160 (74.1%) Aorta ascendens aneurysm155/1161 (13.4%) Previous myocardial infarction325/1159 (28.0%) Chronic heart failure253/1157 (21.9%) Chronic obstructive pulmonary disease97/1163 (8.3%) Current smoking238/1162 (20.5%) Peripheral vascular disease82/1157 (7.1%) Chronic kidney disease131/1159 (11.3%) Diabetes mellitus280/1163 (24.1%) Previous stroke75/1160 (6.5%) Chronic arterial hypertension963/1159 (83.1%)Drug history no./total no. (%) Beta blocker721/1163 (62.0%) ACE inhibitor591/1163 (50.8%)Logistic EuroSCORE4.2 ± 2.5Type of surgery performed --- no./total no. (%) Coronary artery bypass graft (alone)506/1163 (43.5%) Aortic valve replacement/ reconstruction (alone)247/1163 (21.2%) Mitral valve replacement/ reconstruction (alone)40/1163 (3.4%) Aorta ascendens replacement (alone)35/1163 (3.0%) Combined procedures318/1163 (27.3%) Other type of surgery^a^17/1163 (1.5%)Time of procedures --- minutes / total no. Duration of cardiopulmonary bypass231.5 ± 59.8 / 1159 Duration of aortic cross clamping77.6 ± 25.5 / 1156Endpoints (adjusted) Death --- no. (%)9/1163 (0.8%) Myocardial infarction --- no. (%)87/1026 (8.5%) Stroke --- no. (%)17/1106 (1.5%) Acute renal failure --- no. (%)52/1072 (4.9%) New-onset atrial fibrillation --- no. (%)242/882 (27.4%) Delirium --- no. (%)148/967 (15.3%)^a^Plus--minus values are means ± SD. EuroSCORE denotes European System for Cardiac Operative Risk Evaluation. Note that patients could have had multiple events, e.g. patients suffering from both stroke and acute renal failure. Delirium was assessed by the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU Score)

Genotyping {#Sec5}
----------

Genomic DNA was isolated from whole blood of patients using standard procedures. Genotyping was performed for 1224 samples (500 cases and 724 controls) on the Illumina Human CoreExome-24 BeadChip (Illumina, Inc., San Diego, CA, USA) comprising 547,644 markers.

Quality control of genotyped data {#Sec6}
---------------------------------

Markers were called using zCall \[[@CR12]\], an algorithm specifically designed for calling low frequency variants. Samples with the following criteria were excluded: Call rate \< 98%, heterozygosity \> mean + 3x standard deviation (SD), duplicate samples and related samples (IBD \> 0.185). Equally, markers with the following criteria were excluded: Call rate \< 95%, failing Hardy-Weinberg-equilibrium tests in controls (*p* \< 0.00001), markers mapping to chromosome 0, markers with differential missingness between batches (*p* \< 10^− 5^) duplicate and triallelic markers as well as INDELs. For the principal components analysis (HAPMAP PCA), data were merged to the HAPMAP Phase III CEU, CHB and YRI populations. Variants with a minor allele frequency (MAF)-threshold smaller than 0.05 and with a *p*-value of the statistical test for Hardy Weinberg Equilibrium (HWE) in control samples p \< 10^− 5^ were excluded. A batch QC was performed on the remaining samples. Data were again analyzed using PCA and flashpca \[[@CR13]\]. Samples outside the rectangle \[median + − 3\* standard deviation\] were excluded from the analysis. This left 1170 samples and 522,502 variants for analysis.

Phasing and imputation {#Sec7}
----------------------

Data were then phased using SHAPEIT v2 \[[@CR14]\], excluding all variants not matching to the 1000 Genomes Phase I variants according to their allelic information and using only chromosomes 1 to 22. Data were phased using 100 states, 7 burn, 8 prune and 20 main iterations as well as an effective cohort size of 11,418. Data were then imputed using IMPUTE2 v3.0 \[[@CR15]\] in fragments of 5 Mb. Fragments comprising less than 200 variants were merged before imputation. Imputation was performed using the 1000 Genomes Phase I cohort as reference with 20,000 Ne, 250 buffer and 10 burnin and 30 main iterations as well as 80 k and 500 k_hap, 3 outdp. Genotyped data were kept and not overwritten by IMPUTE2. Following imputation markers with an imputation INFO-Score \< 0.8 were excluded, leaving 9,007,469 variants on chromosomes 1 to 22 for analysis.

Statistical analysis {#Sec8}
--------------------

Analysis was performed on 1163 samples. 7 of the above samples were excluded with missing phenotype data. Association tests were performed using PLINK v1.9 \[[@CR16]\]. Statistical analysis of phenotypic data was performed using R (v3.0.2). Fisher's exact test was used for the analysis of categorical and binary data, Student's t-tests were used for the analysis of continuous data. Also, to take into account possible combined effects of the investigated clinical outcomes, we performed a variable selection algorithm using a logistic regression and a stepwise procedure (forwards and backwards) based on the Akaike Information Criterion (AIC) in R as well as a random forest approach using r2VIM \[[@CR17]\] with 500 trees, mtry = 1/3 node size proportion of 10% and 5 runs. Random forest, when using regression mode for a binary outcome, will return probabilities of class membership. The overlap of these three methods was calculated. Variables that occurred more than 2 times were used.

r2vim is a feature selection method that uses relative importance measures to estimate the predictive power of, in this case, covariates in respect to the outcome (here disease) using a random forest approach and is described further in \[[@CR17]\]. Using these relative importance measures, features that are correlated with the outcome are selected. r2vim is a package that is available in R. In a stepwise regression approach the stepAIC function of R can be used to build statistical models (starting from a null model that contains no variables in forward selection and from the full model containing all covariates in backwards selection) that contain any number of covariates. The final model then contains all variables that are most predictive for the outcome. In each step a covariate is added or deleted and the improvement of the model is tested against a previous model using the AIC. The AIC is a statistical measure of the goodness of fit of a model to a particular dataset (in this case disease outcome and clinical phenotypes).

Logistic regression analysis was performed on AF, delirium, MI, renal failure, stroke and the composite. The composite is a "compound" phenotype stating whether or not a sample had a phenotype or not. Genotypes were presented as dosage data between 0 and 2 and the *p*-value of association as well as the Odds ratios and their respective 95% confidence intervals were recorded. All analyses were adjusted for EuroSCORE (European System for Cardiac Operative Risk Evaluation) \[[@CR18]\], age, diabetes mellitus, type of surgery, and baseline creatinine. Analysis of MI was adjusted for use of any cardiac assist device; stroke for severe sepsis/ septic shock; AF for cholesterol lowering drugs and smoking; delirium for any delirium medications, re-thoracotomy, cholesterol lowering drugs, center, NYHA (New York Heart Association) class, severe sepsis/ septic shock; renal failure was not adjusted for any additional covariate. Since one individual might have multiple of the outcomes, two types of analyses were performed: adjust each phenotype for each of the other outcomes to identify variants unique for each phenotype or without adjusting for other outcomes. Here, variants that might overlap between the outcomes are analyzed. A complete list of all adjustments is provided in the supplementary (Additional file [3](#MOESM3){ref-type="media"}: Table S1).

In this analysis we considered the widely excepted *p*-value threshold of 5 × 10^− 8^ as genome-wide significant and 1 × 10^− 5^ as nominally significant.

In total, 882 samples were analyzed for AF, 967 for delir, 1026 for MI, 1072 for renal failure and 1106 for stroke.

Results {#Sec9}
=======

Baseline characteristics {#Sec10}
------------------------

A total of 1403 patients underwent randomization in the RIPHeart study, 1170 of these patients were included in the GWA analysis (Fig. [1](#Fig1){ref-type="fig"}). Baseline demographic and clinical characteristics are shown in Table [1](#Tab1){ref-type="table"}. A wide range of cardiac surgical procedures were included. More than 27% of the original patients had congestive heart failure with NYHA class III or higher and 31% of patients had an EuroSCORE ≥6 or higher before surgery representing a high proportion of high-risk patients \[[@CR6]\].Fig. 1Randomization and Follow-up. Of the 1403 randomized patients, 1170 were included in the GWAS annotation analysis

Postoperative AF was seen in 27.4% (242/882) of the patients. Delirium occurred in 15.3% (148/967), MI in 8.5% (87/1026), acute renal failure in 4.9% (52/1072) and stroke in 1.5% (17/1106).

Explorative genotype analysis {#Sec11}
-----------------------------

A total 9,007,469 imputed markers with an imputation info score higher than 0.8 were available for analysis. We performed analyses with and without an adjustment for all other outcomes and a composite. The GWAS results are depicted using Manhattan plots (Additional file [4](#MOESM4){ref-type="media"}: Figure S1) and quantile-quantile (Q-Q) plots (Additional file [5](#MOESM5){ref-type="media"}: Figure S2) for each analysis and each complication. In this analysis we considered the widely excepted p-value threshold of 5 × 10^− 8^ as genome-wide significant and 1 × 10^− 5^ as nominally significant. Results presented were performed with adjustment for all other outcomes and the composite.

Only one SNP reached genome-wide significance of *p* \< 5 × 10^− 8^(rs78064607, located in an intron of PH domain and leucine rich repeat protein phosphatase 2 gene (*PHLLP2*), *p* = 3.77 × 10^− 8^, (OR_L95 = 0.01, OR_U95 = 0.09, OR with 95% CI 0.02) and was associated with *renal failure*.

The complete list of SNPs showing associations with genes and exhibit the pre-defined p-value of *p* \< 1 × 10^− 5^ from the GWAS with regard to AF, MI, delirium, and renal failure, and stroke is shown in the Additional file [6](#MOESM6){ref-type="media"}: Table S2. SNPs with lowest *p*-values for each complication are shown in Table [2](#Tab2){ref-type="table"}.Table 2List of related SNPs. Summary of SNPs with lowest p-values, influencing known gene loci for each complication, adjusted for each complicationChrSNPBase pairGene symbolGene*P* valueOR with 95% CIOR_L95OR_U95complication2rs755760048,772,202STON1Stonin1, may be involved in the endocytic machinery7.25e-070.490.370.65AFF3rs115155878114,055,988ZBTB20Zinc finger and BTB domain containing 20, may be a transcription factor that may be involved in hematopoiesis, oncogenesis and immune response8.45e-070.210.110.39AFF13rs956302751,708,406LINC00371Long intergenic non-protein coding RNA 3719.82e-070.560.450.71AFF5rs457458189,925,895GPR98G protein-coupled receptor 98, receptor that may have an important role in the development of the central nervous system2.43e-060.540.420.70AFF2rs1300871865,961,565AC074391.1lincRNA9.99e-070.450.330.62DELIR14rs18862351646,926,170LINC00871Long intergenic non-protein coding RNA 8714.02e-060.020.000.10DELIR3rs72747660,316,417FHITFragile histidine triad1.70e-060.460.330.63MI7rs969096940,541,259SUGCTSuccinyl-CoA-glutarate-CoA-transferase1.19e-060.440.310.61MI**16rs7806460771,723,181PHLPP2PH domain and leucine rich repeat protein phosphatase 2, plays a crucial role after I/R injury in the brain and oxidative stress injury in the kidney.3.77e-080.020.010.09RENFAIL**8rs189437718134,655,419SNORA40Small nucleolar RNA, H/ACA Box 403.60e-070.050.010.15RENFAIL1rs7265481521,354,625EIF4G3Eukaryotic Translation Initiation Factor 4 Gamma 36.79e-070.110.050.27RENFAIL**11rs77876049122,936,811HSPA8Heat shock protein 8, HSPA8 seems to play an important role in the regulation of cellular processes after I/R injury both in the heart and in the brain.9.14e-060.250.140.46RENFAIL7rs7999561933,511,328BBS9Bardet-Biedl Syndrome 9, mutations in this genes are associated with the Bardet-Biedl syndrome, which is characterized by renal failure3.35e-070,0010.000.06STROKE**3rs181832941189,567,428TP63Tumor protein p633.65e-070.010.000.06STROKE18rs14091471141,414,229RNU6-443PRNA, U6 small nuclear 443, pseudogene4.07e-070.040.010.13STROKE**1rs192540202237,511,541RYR2Ryanodine receptor 2, calcium channel in the myocard muscle6.33e-070.020.000.08STROKE**Bold: genes with supposed association to I/R injury

SNPs with lowest p-values located in regions associated with genes in patients with complications after cardiac surgery, adjusted for each outcome are: *STON1* (stonin1, rs7557600, *p* = 7.25 × 10^− 7^), *ZBTB20* (Zinc finger and BTB domain containing 20, rs115155878, *p* = 8.45 × 10^− 7^), *LINC00371* (Long intergenic non-protein coding RNA 371, rs9563027, *p* = 9.82 × 10^− 7^) and *GPR98* (G protein-coupled receptor 98, rs4574581, *p* = 2.43 × 10^− 6^) for *AF*, *AC074391.1* (rs13008718, *p* = 9.99 × 10^− 7^), *LINC00871* (Long intergenic non-protein coding RNA 871, rs1886223516, *p* = 4.02 × 10^− 6^) for *delirium*, *FHIT* (Fragile histidine triad, rs727476, *p* = 1.70 × 10^− 6^) and *SUGCT* (Succinyl-CoA-glutarate-CoA-transferase, rs9690969, *p* = 1.91 × 10^− 6^) for *MI*, *SNORA40* (Small nucleolar RNA, H/ACA Box 40, rs189437718, *p* = 3.60 × 10^− 7^), *EIF4G3* (Eukaryotic Translation Initiation Factor 4 Gamma 3, rs72654815, *p* = 6.79 × 10^− 7^) for *renal failure* and *BBS9* (Bardet-Biedl Syndrome 9, rs79995619, *p* = 3.35 × 10^− 7^), *TP63* (Tumor protein p63, rs181832941, *p* = 3.65 × 10^− 7^), *RNU6-443P* (RNA, U6 small nuclear 443, rs140914711, *p* = 4.07 × 10^− 7^) and (*RyR2* (Ryanodine receptor 2, rs192540202, *p* = 6.33 × 10^− 7^) for *stroke*.

Besides adjusted analysis, the composite, meaning a "compound" phenotype stating whether or not a sample had a phenotype or not, comprises five SNPs, three with association with genes: *RP5-968 J1.1* (rs200890 *p* = 1.19 × 10^− 6^), *DUSP4* (Dual Specificity Phosphatase 4, rs4732926, *p* = 5.53 × 10^− 6^, OR_L95 = 0.47, OR_U95 = 0.74) and *WLS* (Wntless Wnt Ligand Secretion Mediator) and *GNG12-AS1 (*GNG Antisense RNA 1), (rs74081211, *p* = 6.25 × 10^− 6^).

Loci of SNPs with lowest p-values in genes are shown in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2**a-f** SNP loci with lowest *p*-values associated with **a**) AF, **b**) delirium, **c**) MI, **d**) renal failure and **e**) stroke

Discussion {#Sec12}
==========

As postoperative organ dysfunction is common after cardiac surgery, previous studies have performed preoperative genomic characterization of patients to identify genotypes, which render the patients vulnerable for the development of a specific organ dysfunction. Kertai et al. identified genetic variants in patients exhibiting AF and MI after cardiac surgery \[[@CR3], [@CR4]\]. Another recent study reported genetic variants concerning acute kidney injury after cardiac surgery \[[@CR5]\]. To identify common genetic variants associated with the main complications AF, delirium, MI, acute renal failure and stroke, we performed a GWAS study with DNA samples of 1170 patients after cardiac surgery. We identified one SNP reaching genome-wide significance (p \< 5 × 10^− 8^) and nearly 150 SNPs which reached the a priori defined discovery threshold of p \< 1 × 10^− 5^. Since one individual might have multiple of the outcomes, we performed two types of analyses. Either we adjusted each phenotype of the other outcomes to identify variants unique for each phenotype or performed analyses without adjusting for each other. Here, variants might overlap between the outcomes and influenced genes could have effects to several organs. Besides, we identified a "compound" phenotype stating whether or not a sample has a phenotype or not.

*DUSP4* (rs4732926, Dual Specificity Phosphatase 4) was identified as a compound phenotype. *DUSP4* is an inducible nuclear phosphatase that is involved in regulating cardiovascular function under oxidative stress \[[@CR19]\]. *DUSP4* −/− mice showed an increase of I/R-induced infarct caused by an over activation of p38, a stress-activated and pro-inflammatory kinase. In accordance to this, overexpression of *DUSP4* in endothelial cells prevents hypoxia/ reoxygenation-induced apoptosis via the upregulation of eNOS \[[@CR20]\]. Therefore, it would be worthwhile to have a closer look inside the exact role of *DUSP4* during cardiac surgery.

rs78064607, the only SNP with genome-wide significance in our study is located in *PHLPP2* (PH Domain and Leucine Rich Repeat Protein Phosphatase 2) and was associated with increased risk of acute kidney injury. *PHLPP2* is a phosphatase, important for the regulation of Akt kinases and PKC isoforms \[[@CR21], [@CR22]\]. Akt belongs to the so called pro-survival kinases, involved in the protective pathway during myocardial ischemia/ reperfusion \[[@CR23]\]. Akt controls the balance between cell survival and apoptosis, as well as proliferation and cellular quiescence. Activation of PI3K/Akt seems to be protective against I/R injury. *PHLPP2* dephosphorylates Akt (precisely Akt1 and Akt3) and therefore inactivates Akt. *PHLPP2* inhibition leads to neuronal protection after cerebral ischemia/reperfusion injury in rats \[[@CR24], [@CR25]\]. The imbalance of cell pro-death and pro-survival signaling pathways determines the neuronal fate during ischemia/reperfusion injury. In a rat model of I/R injury it was shown that inhibition of *PHLPP2* attenuates cell death in I/R injury. Very recently, it was demonstrated that *PHLPP2* plays a pivotal role in acetaminophen induced oxidative renal toxicity by influencing Nrf2 stability via Akt1/Gsk3b/Fyn kinase axis \[[@CR26]\]. Down regulation of *PHLPP2* by morin, a bioflavonoid, significantly prevented the toxicity induced renal damages. In this respect, down regulation of *PHLPP2* may provide positive effects in the kidney and in the brain, two vital organs affected by cardiac surgery. In line with our GWAS of complications after cardiac surgery we found the SNP rs78064607 located in the *PHLPP2* gene with a genome-wide significance. Because the SNP is located in the intron region or intergenic region, respectively, of the gene, the exact effect on the *PHLPP2* gene cannot be evaluated. Probably an enhancer/ silencer region is affected, leading to up or down regulation of the *PHLPP2* gene. Association of possible changes in the expression of *PHLPP2* with increased occurrence of complications, especially RENFAIL after cardiac surgery could be a hind of an increased expression of *PHLPP2*. But this assumption is highly speculative and has to be confirmed by further gene expression analyses.

*ZBTB20* (Zinc finger and BTB domain containing 20, rs115155878 is related to this gene) is widely expressed in human hematopoietic cells, including DCs, monocytes, B cells and T cells. *ZBTB20* deficiency in mice attenuated TLR-triggered production of pro inflammatory cytokines in macrophages \[[@CR27]\]. This could have an influence of mechanisms within the scope of I/R.

For stroke, rs4098926, the SNP with the lowest *p*-value for this complication is located in the *BBS9* gene. *BBS9* is also known as parathyroid hormone-responsive B1 gene (PTHB1). Mutations of *BBS9* are related with the Bardet-Biedl syndrome, a rare genetic disorder with highly variable symptoms. The underlying cause is malfunction of primary cilia, a key component of cellular communication function as signal transduction antennae. Kidney disease is a key feature and major cause of early mortality of patients with Bardet-Biedl syndrome. Intact cilia are critical under kidney injury conditions caused by ischemia/ reperfusion, because cilia are sensors of damages and activate cell proliferation probably to promote renal recovery \[[@CR28], [@CR29]\]. Changes in *BBS9* could contribute to higher complication rate concerning the kidney in patients undergoing cardiac surgery and further investigations of involvement of *BBS9* in postoperative renal injuries are worthwhile. Additionally, the exact role of *BBS9* in the pathogenesis of stroke after cardiac surgery has to be evaluated.

rs192540202 is located in an intron region of *RyR2* (ryanodine receptor 2). *RyR2* is primarily found in cardiac muscle and forms a Ca^2+^ release channel on the membrane of the sarcoplasmic reticulum. Abnormal *RyR2* function is recognized as an important part of the pathophysiology of heart failure, especially contractile dysfunction, arrhythmia and sudden death \[[@CR30], [@CR31]\]. Numerous studies revealed that abnormal Ca^2+^ homeostasis may play an important role in the electric and contractile remodeling accompanying sustained atrial fibrillation \[[@CR32], [@CR33]\]. Very recently, Xie et al. identified a link between oxidative stress and *RyR2* \[[@CR34]\]. Mice with mutations in the *RyR2* receptor exhibited mitochondrial dysfunction, increased reactive oxygen species production and increased AF susceptibility. Because oxidative stress and mitochondria dysfunction plays a pivotal role in the pathogenesis of I/R injury of organs, changes in *RyR2* receptor associated with disturbed Ca^2+^ homeostasis could contribute to higher risk of complication after cardiac surgery.

*RyR2* also has an impact on Ca^2+^ homeostasis in the brain during cerebral ischemia \[[@CR35]\]. In a rat model of brain ischemia, Bull et al. could demonstrate that amplification of Ca^2+^ by *RyR2* entry signals may contribute to cortical neuronal death.

Very interestingly, knockdown of *RyR2* in a spinal cord injury model in rats inhibited the increase of pro-inflammatory cytokines, improved mitochondrial dysfunction and reduced oxidative stress \[[@CR36]\]. Because release of pro-inflammatory cytokines, massive ROS production and mitochondrial dysfunction are the main causes of I/R injury of organs, examination of the exact role of *RyR2* could be very interesting.

rs77876049 is located in the *HSPA8* gene. Although this SNP has a higher p-value, it is reasonable to have a closer look at this protein because of its interesting involvement in the mechanisms of I/R injury. *HSPA8* (Heat Shock Protein 8, also known as Hsc70 or Hsp73) is a member of the heat shock protein 70 family and facilitates the correct folding of newly translated or misfolded proteins. *HSPA8* plays an important role in signal transduction, apoptosis, protein homeostasis, cell growth and differentiation. Zou et al. could demonstrate that *HSPA8*, constitutively expressed in the myocardium, is released during ischemia/ reperfusion and induces the myocardial inflammatory response and modulates cardiac function \[[@CR37]\]. Acute myocardial ischemia can lead to a cascade of cellular and ischemic tissue, causing irreversible damage. In myocardial ischemia and reperfusion, the myocardial cells release *HSPA8* and reduce myocardial cell injury \[[@CR38]\]. Thus, *HSPA8* plays a critical role in regulating the myocardial innate immune system and cardiac function after ischemia/ reperfusion. Probably, *HSPA8* specifically has a protective effect in patients undergoing open heart surgery \[[@CR39]\]. It has also been shown that Chaperone-mediated autophagy (CMA), under involvement of *HSPA8*, of damaged or leaky *RyR2* receptors after I/R may play a protective role after I/R injury and could contribute to myocardial remodeling \[[@CR40]\]. A combined functional impairment of *HSPA8* and *RyR2* in patients undergoing cardiac surgery could contribute to increased myocardial complications because of lack of functioned *RyR2* receptors and the inability to remove damaged *RyR2* receptors by CMA. *HSPA8* also plays a protective role in the process of ischemic stroke by protection of nerve cells and inhibition of neuronal apoptosis \[[@CR41]--[@CR43]\]. *HSPA8* seems to play an important role in the regulation of cellular processes after I/R injury both in the heart and in the brain. Therefore, patients with variants in this gene might have an increased complication rate after cardiac surgery. So, *HSPA8* might be a prognostic factor, but validation of these findings will require additional studies with independent subject panels.

None of the further identified genetic variants associated with atrial fibrillation \[[@CR44], [@CR45]\], myocardial infarction \[[@CR46], [@CR47]\], stroke \[[@CR48]\] or renal dysfunction \[[@CR49]\] in non-surgical patients was found in our analyses. In contrast, some of the described genetic variants associated with complications after cardiac surgery, namely *BBS9* in renal dysfunction \[[@CR5]\], were found in our study. This indicates a unique pathogenesis in the subset of ischemia/ reperfusion after cardiac surgery that differs from pathogenesis in non-surgical patients. Surprisingly, neither Kertai et al. \[[@CR3]\] nor our study could replicate previously reported associations between common genetic variants at the 9p21 locus and risk for myocardial infarction after cardiac surgery \[[@CR50], [@CR51]\]. Probably, variations in study design or differences in data analysis could be reasons for these variations and further studies are needed to explain these discrepancies.

Conclusions {#Sec14}
===========

Here we report the first GWAS in a cohort of patients at risk of AF, delirium, MI, acute renal failure and stroke after cardiac surgery. We identified several polymorphisms associated with these complications. In most cases, loci are noncoding, and many loci are far from discovered genes in non-coding regions, the effects of SNPs on genes are completely unknown or the functions of the influenced genes are unknown. Furthermore, GWAS almost exclusively detects the effects of common SNPs, any rare variants will not be detected. Nevertheless, we identified some very interesting potential correlations between genetic polymorphisms and the occurrence of complications. In particular, the described concurrence of *HSPA8* and *RyR2* for atrial fibrillation and myocardial infarction, the involvement of *DUSP4* in I/R injury, the role of *PHLPP2* in developing complications after cardiac surgery and the involvement of *BBS9* in renal dysfunction could be interesting for further future examinations. Follow-up studies are needed to transfer these findings into biological insights that could result in predictive and therapeutic advances in the perioperative care of cardiac surgery patients.
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